Clinical Trials on Maladie de Gaucher de type 3

Total 122 results

PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
AVROBIO

Withdrawn

An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

Gaucher Disease, Type 3
Sanofi

Recruiting

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)

Gaucher's Disease Type III

United States, Germany, Hungary, France, China, Japan, Canada, Argentina, Italy, Turkey
KemPharm Denmark A/S

Terminated

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Gaucher Disease, Type 1 | Gaucher Disease, Type 3

India
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
CANbridge (Suzhou) Bio-pharma Co., Ltd.

Recruiting

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Gaucher Disease, Type 1 | Gaucher Disease, Type 3

China
Yale University
Juvenile Diabetes Research Foundation

Terminated

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Type 1 Diabetes | De Novo Lipogenesis

United States
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients (ApoC1)

diabète de Type 1

France
Genzyme, a Sanofi Company

Active, not recruiting

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (LEAP)

Gaucher Disease Type 1 | Gaucher Disease Type 3

Germany, United States, Japan, United Kingdom
Baylor Research Institute
Texas Scottish Rite Hospital for Children

Withdrawn

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Gaucher Disease Type 1 | Gaucher Disease Type 3

United States
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...

Completed

A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma (DENDR-STEM)

de Novo Glioblastoma
Shire

Completed

Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

Gaucher Disease, Type 3

Egypt, India, Tunisia
Ari Zimran
Pfizer

Active, not recruiting

A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

Gaucher Disease, Type 3

Israel, Turkey, India
University of Minnesota

Recruiting

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

Gaucher Disease, Type 3

United States
Fudan University

Unknown

De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations

Oropharyngeal Carcinoma | De-escalation

China
Fudan University

Recruiting

Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Oropharyngeal Carcinoma | Immune Checkpoint Inhibitor | De-escalation

China
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
University Hospital, Caen
Laphal

Completed

Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. (MAG 2002)

Multiple Myeloma de Novo Treatment

France
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Nasopharyngeal Carcinoma | De-escalation Therapy

China
University of California, San Francisco
Duke University

Recruiting

In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases (IUERT)

Wolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VII

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | De-escaltion Therapy

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate (LAL1913)

Secondary | De Novo | Untreated Philadelphia Positive Acute Lymphoblastic Leukemia | Low-dose Corticosteroids Pretreatment

Italy
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center

Completed

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
Institut Curie
National Cancer Institute, France; Fondation ARC

Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Acute Myeloid Leukemia, in Relapse | Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome | de Novo Acute Myeloid Leukemia at Diagnostic

France
University of Washington
National Cancer Institute (NCI); Bayer

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
GlaxoSmithKline

Completed

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Carcinoma, Renal Cell
Hannover Medical School
University Hospital, Ghent; Johann Wolfgang Goethe University Hospital; University... and other collaborators

Unknown

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

De Novo Akute Myeloid Leukemia (AML) | Secondary Acute Myeloid Leukemia (AML) | Refractory Anemia With Excess of Blasts in Transformation

Germany
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
City of Hope Medical Center

Completed

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndromes

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Case Comprehensive Cancer Center

Completed

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts

United States
University of Southern California

Completed

Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery

Ganglion Cysts | Carpal Tunnel Syndrome | Dupuytren Contracture | Trigger Digit | De Quervain Disease

United States
University of Texas at Austin

Unknown

Different Sutures in Hand Surgery

Ganglion Cysts | Carpal Tunnel Syndrome | Trigger Finger | Dupuytren Contracture | All Minor Hand Surgery Including | De Quervain Syndrome

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
Dana-Farber Cancer Institute
Gateway for Cancer Research

Recruiting

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Epithelioid Sarcoma | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Rhabdoid Tumor of the Kidney | Chordoma (Poorly Differentiated or De-differentiated) | Other INI1 Negative Tumors (With PI Approval) | Other SMARCA4-deficient Malignant Tumors (With PI Approval)

United States
National Cancer Institute (NCI)

Terminated

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | de Novo Myelodysplastic Syndromes

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States

Clinical Trials on Maladie de Gaucher de type 3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations